Hepatitis C: The role of new interferons in the era of STAT-C

Nature Reviews Gastroenterology and Hepatology

Volumn 6, Issue 9, 2009, Pages 509-511

  Moucari, Rami ^a   Marcellin, Patrick ^a  

^a BEAUJON HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALBINTERFERON ALPHA2B; ANTIVIRUS AGENT; BOCEPREVIR; CONSENSUS INTERFERON; INTERFERON STAT C; PEGINTERFERON ALPHA2A; RIBAVIRIN; TELAPREVIR; UNCLASSIFIED DRUG; VIRUS RNA;

ANTIVIRAL THERAPY; ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; PRIORITY JOURNAL; VIRUS LOAD;

ALBUMINS; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; INTERFERON TYPE I, RECOMBINANT; POLYETHYLENE GLYCOLS; RIBAVIRIN; TREATMENT OUTCOME;

EID: 69949102964     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2009.141     Document Type: Article

References (12)

1. Marcellin, P. Hepatitis B and hepatitis C in 2009. Liver Int. 29 (suppl. 1), 1-8 (2009).
2. shiffman, M. L. et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 126, 1015-1023 (2004).
3. Moucari, R. et al. High predictive value of early viral kinetics in retreatment with peginterferon and ribavirin of chronic hepatitis C patients non-responders to standard combination therapy. J. Hepatol. 46, 596-604 (2007).
4. Poynard, T. et al. Peginterferon alfa-2b and ribavirin: Effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology 136, 1618-1628 (2009).
5. Moucari, R. et al. insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCv RnA level, and liver fibrosis. Gastroenterology 134, 416-423 (2008).
6. Di Bisceglie, A. M. et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N. Engl. J. Med. 359 2429-2441 (2008).
7. Jensen, D. M. et al. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-a2b: A randomized trial. Ann. Intern. Med. 150, 528-540 (2009).
8. Bacon, B. R. et al. Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ ribavirin: DiReCT results. Hepatology 49, 1838-1846 (2009).
9. Leevy, C. B. Consensus interferon and ribavirin in patients with chronic hepatitis C who were nonresponders to pegylated interferon alfa-2b and ribavirin. Dig. Dis. Sci. 53, 1961-1966 (2008).
10. neslon, D. R. et al. sustained virologic response with albinterferon alfa-2b/ribavirin treatment in prior interferon therapy nonresponders [abstract]. Hepatology 46 (suppl. 1), 256A (2007).
11. Manns, M. et al. Telaprevir in hepatitis C genotype-1-infected patients with prior nonresponse, viral breakthrough or relapse to peginterferon alfa-2a/b and ribavirin therapy: SvR results of the PROve 3 study [abstract]. J. Hepatol. 50 (suppl. 1), s379 (2009).
12. schiff, e. et al. Boceprevir (B) combination therapy in null responders (nR): Response dependent on interferon responsiveness [abstract]. J. Hepatol. 48 (suppl. 2), s46 (2008).